| 词条 | Romosozumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 464383486 | type = mab | image = | alt = | mab_type = mab | source = zu/o | target = Sclerostin | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 909395-70-6 | ATC_prefix = M05 | ATC_suffix = BX06 | PubChem = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | KEGG = D10156 | KEGG_Ref = {{keggcite|changed|kegg}} | C=6452 | H=9926 | N=1714 | O=2040 | S=54 | molecular_weight = 145.9 kg/mol }} Romosozumab (AMG 785) is a humanized monoclonal antibody that targets sclerostin for the treatment of osteoporosis.[1] Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density, but it has not been approved the regulatory agencies and is not in widespread clinical use. Romosozumab was originally discovered by Chiroscience,[2] which was acquired by Celltech (now owned by UCB).[3] Celltech entered in a partnership with Amgen in 2002 for the product's development.[4] In 2016 results from 12 months of a clinical study were reported.[5] Patients given romosozumab had a lower risk of vertebral fracture than patients given a placebo. Some results from the FRAME[6] and ARCH clinical studies were reported on in 2017.[7] Both studies showed patients who took romosozumab as part of a combination therapy regimen experienced fewer new vertebral fractures than patients in control groups. References1. ^{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab|publisher=American Medical Association|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/romosozumab.pdf}} {{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}{{monoclonal-antibody-stub}}{{musculoskeletal-drug-stub}}2. ^{{cite news |url= https://www.businessweekly.co.uk/news/cambridge-torchbearers/cream-life-science-entrepreneurs%E2%80%99-first-venture-was-selling-doughnuts |title=Cream of life science entrepreneurs’ first venture was selling doughnuts |last=Quested |first=Tony | name-list-format = vanc |date=June 7, 2015 |work=Business Week |access-date=December 24, 2018 |publisher=Q Communications |location=Cambridge, England }} 3. ^{{cite journal | vauthors = Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA | display-authors = 6 | title = Osteocyte control of bone formation via sclerostin, a novel BMP antagonist | journal = The EMBO Journal | volume = 22 | issue = 23 | pages = 6267–76 | date = December 2003 | pmid = 14633986 | doi = 10.1093/emboj/cdg599 }} 4. ^{{cite web | title = Celltech group Interim Report 2002 | url = http://media.corporate-ir.net/media_files/LSE/CLL.UK/reports/interim2002.pdf | publisher = Celltech Group plc }} 5. ^{{cite journal | vauthors = Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A | display-authors = 6 | title = Romosozumab Treatment in Postmenopausal Women with Osteoporosis | journal = The New England Journal of Medicine | volume = 375 | issue = 16 | pages = 1532–1543 | date = October 2016 | pmid = 27641143 | doi = 10.1056/NEJMoa1607948 }} 6. ^{{ClinicalTrialsGov|NCT01575834|Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (FRAME)}} 7. ^{{cite web | first = Nancy | last = Walsh | name-list-format = vanc | url = https://www.medpagetoday.com/meetingcoverage/asbmr/67832 | title = Bone Loss Drug Effective, But is it Safe? | date = September 2017 | work = MedPage Today }} 1 : Amgen |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。